Sage Therapeutics Inc. (SAGE) Now Covered by Analysts at Stifel Nicolaus
Equities researchers at Stifel Nicolaus assumed coverage on shares of Sage Therapeutics Inc. (NASDAQ:SAGE) in a note issued to investors on Monday. The firm set a “buy” rating on the biopharmaceutical company’s stock.
Several other analysts also recently weighed in on SAGE. BMO Capital Markets reissued a “buy” rating and issued a $57.00 target price on shares of Sage Therapeutics in a report on Friday, August 12th. Zacks Investment Research raised Sage Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 26th. Canaccord Genuity set a $110.00 target price on Sage Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 6th. Raymond James Financial Inc. started coverage on Sage Therapeutics in a report on Tuesday, September 13th. They issued an “outperform” rating and a $75.00 target price for the company. Finally, Cowen and Company reissued a “buy” rating on shares of Sage Therapeutics in a report on Monday, September 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $67.83.
Sage Therapeutics (NASDAQ:SAGE) opened at 51.60 on Monday. The stock’s market cap is $1.92 billion. The firm’s 50-day moving average price is $44.18 and its 200-day moving average price is $38.51. Sage Therapeutics has a 12 month low of $26.28 and a 12 month high of $62.64.
Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by $0.05. On average, analysts predict that Sage Therapeutics will post ($4.35) earnings per share for the current year.
In other Sage Therapeutics news, CFO Kimi Iguchi sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, September 7th. The stock was sold at an average price of $40.93, for a total transaction of $102,325.00. Following the transaction, the chief financial officer now owns 81,239 shares in the company, valued at approximately $3,325,112.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.60% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas boosted its stake in Sage Therapeutics by 38.2% in the second quarter. Teacher Retirement System of Texas now owns 3,522 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 973 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Sage Therapeutics by 129.1% in the third quarter. BNP Paribas Arbitrage SA now owns 2,369 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,335 shares in the last quarter. Legal & General Group Plc boosted its stake in Sage Therapeutics by 30.6% in the second quarter. Legal & General Group Plc now owns 5,414 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 1,268 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Sage Therapeutics during the second quarter worth $208,000. Finally, Cowen Group Inc. purchased a new stake in Sage Therapeutics during the second quarter worth $211,000. Institutional investors and hedge funds own 85.82% of the company’s stock.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.
Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.